S&P 500   3,986.58 (-0.41%)
DOW   32,365.02 (-0.60%)
QQQ   309.96 (-0.12%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.15 (+0.22%)
AMZN   100.21 (-0.40%)
TSLA   194.64 (-1.49%)
NVDA   270.17 (+3.12%)
NIO   9.23 (-0.43%)
BABA   84.28 (+0.69%)
AMD   99.06 (+3.26%)
T   18.54 (+0.00%)
F   11.68 (-0.34%)
MU   59.02 (+0.67%)
CGC   1.92 (-2.79%)
GE   90.81 (-1.49%)
DIS   96.20 (-0.35%)
AMC   4.52 (+2.49%)
PFE   40.25 (-1.01%)
PYPL   75.39 (-1.73%)
NFLX   298.36 (-2.43%)
S&P 500   3,986.58 (-0.41%)
DOW   32,365.02 (-0.60%)
QQQ   309.96 (-0.12%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.15 (+0.22%)
AMZN   100.21 (-0.40%)
TSLA   194.64 (-1.49%)
NVDA   270.17 (+3.12%)
NIO   9.23 (-0.43%)
BABA   84.28 (+0.69%)
AMD   99.06 (+3.26%)
T   18.54 (+0.00%)
F   11.68 (-0.34%)
MU   59.02 (+0.67%)
CGC   1.92 (-2.79%)
GE   90.81 (-1.49%)
DIS   96.20 (-0.35%)
AMC   4.52 (+2.49%)
PFE   40.25 (-1.01%)
PYPL   75.39 (-1.73%)
NFLX   298.36 (-2.43%)
S&P 500   3,986.58 (-0.41%)
DOW   32,365.02 (-0.60%)
QQQ   309.96 (-0.12%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.15 (+0.22%)
AMZN   100.21 (-0.40%)
TSLA   194.64 (-1.49%)
NVDA   270.17 (+3.12%)
NIO   9.23 (-0.43%)
BABA   84.28 (+0.69%)
AMD   99.06 (+3.26%)
T   18.54 (+0.00%)
F   11.68 (-0.34%)
MU   59.02 (+0.67%)
CGC   1.92 (-2.79%)
GE   90.81 (-1.49%)
DIS   96.20 (-0.35%)
AMC   4.52 (+2.49%)
PFE   40.25 (-1.01%)
PYPL   75.39 (-1.73%)
NFLX   298.36 (-2.43%)
S&P 500   3,986.58 (-0.41%)
DOW   32,365.02 (-0.60%)
QQQ   309.96 (-0.12%)
AAPL   159.54 (+0.16%)
MSFT   275.90 (+0.77%)
META   203.27 (+0.55%)
GOOGL   105.15 (+0.22%)
AMZN   100.21 (-0.40%)
TSLA   194.64 (-1.49%)
NVDA   270.17 (+3.12%)
NIO   9.23 (-0.43%)
BABA   84.28 (+0.69%)
AMD   99.06 (+3.26%)
T   18.54 (+0.00%)
F   11.68 (-0.34%)
MU   59.02 (+0.67%)
CGC   1.92 (-2.79%)
GE   90.81 (-1.49%)
DIS   96.20 (-0.35%)
AMC   4.52 (+2.49%)
PFE   40.25 (-1.01%)
PYPL   75.39 (-1.73%)
NFLX   298.36 (-2.43%)
NASDAQ:TNYA

Tenaya Therapeutics - TNYA Stock Forecast, Price & News

$2.71
-0.09 (-3.21%)
(As of 03/22/2023 03:25 PM ET)
Add
Compare
Today's Range
$2.67
▼
$2.83
50-Day Range
$2.10
▼
$3.59
52-Week Range
$1.64
▼
$14.43
Volume
112,462 shs
Average Volume
383,465 shs
Market Capitalization
$181.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.33

Tenaya Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
593.4% Upside
$19.00 Price Target
Short Interest
Healthy
2.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$4.56 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.43) to ($2.56) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

124th out of 983 stocks

Biological Products, Except Diagnostic Industry

20th out of 163 stocks

See Top Rated MarketRank™ Stocks Here

TNYA stock logo

About Tenaya Therapeutics (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Receive TNYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNYA Stock News Headlines

March 20, 2023 | americanbankingnews.com
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $19.00 Average Price Target from Analysts
March 14, 2023 | americanbankingnews.com
HC Wainwright Comments on Tenaya Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:TNYA)
March 22, 2023 | Investing Daily (Ad)
This Trade Strategy Outpaces Almost Anything
Despite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. pixel
March 12, 2023 | americanbankingnews.com
Tenaya Therapeutics (NASDAQ:TNYA) PT Lowered to $18.00
March 9, 2023 | markets.businessinsider.com
LifeSci Capital Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)
March 9, 2023 | finanznachrichten.de
Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 8, 2023 | finance.yahoo.com
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 4, 2023 | seekingalpha.com
TNYA Tenaya Therapeutics, Inc.
March 22, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
January 26, 2023 | msn.com
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know
January 25, 2023 | marketwatch.com
New Report on Epilepsy Therapeutics Market: 2023 Complete Research on Prominent Player, Business Prospect, and Growth Rate By 2027
January 11, 2023 | seekingalpha.com
The Take On Tenaya Therapeutics
January 9, 2023 | finance.yahoo.com
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
December 21, 2022 | finance.yahoo.com
Insiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% drop
December 7, 2022 | finance.yahoo.com
Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors
November 28, 2022 | finance.yahoo.com
Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
November 24, 2022 | benzinga.com
Massive Insider Trade At Tenaya Therapeutics
November 24, 2022 | finance.yahoo.com
Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely
November 23, 2022 | technews.tmcnet.com
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference
November 23, 2022 | finance.yahoo.com
Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 | finanznachrichten.de
Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Closing of Public Offering
November 21, 2022 | finance.yahoo.com
Tenaya Therapeutics Announces Closing of Public Offering
November 17, 2022 | finanznachrichten.de
Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Proposed Public Offering
November 17, 2022 | markets.businessinsider.com
Tenaya Therapeutics Prices Public Offering Of 22.61 Mln Shares At $2.60/shr
November 17, 2022 | finance.yahoo.com
Tenaya Therapeutics Announces Pricing of Public Offering
November 16, 2022 | finance.yahoo.com
Tenaya Therapeutics Announces Proposed Public Offering
November 10, 2022 | technews.tmcnet.com
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
See More Headlines
Receive TNYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNYA Company Calendar

Last Earnings
11/10/2021
Today
3/22/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNYA
CUSIP
N/A
CIK
1858848
Web
www.tenayatherapeutics.com
Phone
650-825-6990
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+554.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-123,670,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-54.20%
Return on Assets
-47.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.99
Quick Ratio
7.99

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.64 per share
Price / Book
0.77

Miscellaneous

Outstanding Shares
66,860,000
Free Float
43,970,000
Market Cap
$187.21 million
Optionable
Not Optionable
Beta
2.28

Key Executives

  • Mr. Faraz Ali M.B.A. (Age 49)
    CEO, Sec. & Director
    Comp: $710.77k
  • Dr. Deepak Srivastava M.D. (Age 55)
    Scientific Founder, Chairman of Scientific Advisory Board & Director
    Comp: $18.15k
  • Ms. Leone D. Patterson M.B.A. (Age 59)
    Chief Financial & Bus. Officer
    Comp: $448.55k
  • Dr. Whittemore G. Tingley M.D. (Age 54)
    PH.D., Chief Medical Officer
    Comp: $551.18k
  • Dr. Eric N. Olson Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Dr. Bruce R. Conklin
    Scientific Founder
  • Dr. Saptarsi Haldar M.D.
    Scientific Founder
  • Dr. Sheng Ding
    Scientific Founder
  • Dr. Benoit G. Bruneau Ph.D.
    Scientific Founder
  • Dr. Kee-Hong Kim Ph.D. (Age 56)
    Chief Technology Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TNYA Stock - Frequently Asked Questions

Should I buy or sell Tenaya Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TNYA shares.
View TNYA analyst ratings or view top-rated stocks.

What is Tenaya Therapeutics' stock price forecast for 2023?

6 equities research analysts have issued 1 year price objectives for Tenaya Therapeutics' shares. Their TNYA share price forecasts range from $13.00 to $24.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 578.6% from the stock's current price.
View analysts price targets for TNYA or view top-rated stocks among Wall Street analysts.

How have TNYA shares performed in 2023?

Tenaya Therapeutics' stock was trading at $2.01 on January 1st, 2023. Since then, TNYA stock has increased by 39.3% and is now trading at $2.80.
View the best growth stocks for 2023 here.

When is Tenaya Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our TNYA earnings forecast.

How were Tenaya Therapeutics' earnings last quarter?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.20.

What ETFs hold Tenaya Therapeutics' stock?

ETFs with the largest weight of Tenaya Therapeutics (NASDAQ:TNYA) stock in their portfolio include BlackRock Future Health ETF (BMED).Fidelity Growth Opportunities ETF (FGRO).

When did Tenaya Therapeutics IPO?

(TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

What is Tenaya Therapeutics' stock symbol?

Tenaya Therapeutics trades on the NASDAQ under the ticker symbol "TNYA."

Who are Tenaya Therapeutics' major shareholders?

Tenaya Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (14.66%), Price T Rowe Associates Inc. MD (10.81%), Alyeska Investment Group L.P. (2.50%), Geode Capital Management LLC (1.15%), Trustees of Columbia University in the City of New York (0.71%) and Renaissance Technologies LLC (0.51%). Insiders that own company stock include David V Goeddel, Deepak Srivastava, Eli Casdin, Group Gp Lp Column III and Timothy Hoey.
View institutional ownership trends.

How do I buy shares of Tenaya Therapeutics?

Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tenaya Therapeutics' stock price today?

One share of TNYA stock can currently be purchased for approximately $2.80.

How much money does Tenaya Therapeutics make?

Tenaya Therapeutics (NASDAQ:TNYA) has a market capitalization of $187.21 million. The company earns $-123,670,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis.

How many employees does Tenaya Therapeutics have?

The company employs 106 workers across the globe.

How can I contact Tenaya Therapeutics?

The official website for the company is www.tenayatherapeutics.com. The company can be reached via phone at 650-825-6990 or via email at investors@tenayathera.com.

This page (NASDAQ:TNYA) was last updated on 3/22/2023 by MarketBeat.com Staff